Zacks Research Analysts Decrease Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Equities researchers at Zacks Research dropped their Q4 2024 earnings estimates for shares of Bio-Rad Laboratories in a note issued to investors on Monday, October 14th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.77 for the quarter, down from their previous estimate of $2.78. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.45 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q2 2025 earnings at $2.86 EPS, Q3 2025 earnings at $2.97 EPS and Q3 2026 earnings at $2.94 EPS.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, topping the consensus estimate of $2.12 by $0.99. Bio-Rad Laboratories had a negative net margin of 51.73% and a positive return on equity of 3.77%. The company had revenue of $638.50 million during the quarter, compared to analysts’ expectations of $645.79 million. During the same quarter last year, the business earned $3.00 EPS. The business’s revenue was down 6.3% on a year-over-year basis.

BIO has been the subject of several other research reports. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Citigroup upgraded shares of Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and raised their price objective for the company from $350.00 to $400.00 in a research note on Tuesday, October 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $401.00 price objective on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective for the company. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $368.20.

Bio-Rad Laboratories Stock Down 3.6 %

BIO stock opened at $329.95 on Tuesday. Bio-Rad Laboratories has a one year low of $261.59 and a one year high of $364.24. The stock has a market capitalization of $9.41 billion, a PE ratio of -31.85 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. The company has a fifty day moving average of $329.64 and a 200-day moving average of $306.99.

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the transaction, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Andrew J. Last sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bio-Rad Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of BIO. Van ECK Associates Corp purchased a new stake in shares of Bio-Rad Laboratories during the second quarter worth about $180,040,000. First Eagle Investment Management LLC grew its holdings in shares of Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after buying an additional 634,311 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Bio-Rad Laboratories by 64.4% during the second quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock worth $135,081,000 after buying an additional 193,700 shares in the last quarter. Select Equity Group L.P. grew its holdings in shares of Bio-Rad Laboratories by 26.2% during the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after buying an additional 134,856 shares in the last quarter. Finally, Earnest Partners LLC grew its holdings in shares of Bio-Rad Laboratories by 30.8% during the first quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company’s stock worth $178,091,000 after buying an additional 121,272 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.